Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.

Barrons • Oct 28, 2026

Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the company seeks to increase growth from medicines it owns or co-develops.

MarketBeat • Oct 28, 2026

Genmab Stock Hits 52-Week High - Here's Why

Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline findings from its global Phase 3 LiGeR-HN1 clinical trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting EGFR and LGR5.

Benzinga • Oct 28, 2026

Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript

Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript

Seeking Alpha • Oct 28, 2026

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab versus pembrolizumab in patients with first-line (1L) PD-L1 positive recurrent/metastatic head and neck squ.

Business Wire • Oct 28, 2026

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Biotechnology company Genmab A/S (NASDAQ:GMAB) delivered encouraging clinical updates for its investigational bispecific antibody petosemtamab across two major solid tumor types at the European Society for Medical Oncology Congress 2026, while securing a new clinical oncology partnership with Incyte Corporation (NASDAQ:INCY).

Benzinga • Oct 26, 2026

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC), with responses observed across HPV-positive and HPV-negative disease Phase 3 program in 1L HNSCC is ongoing, with topline data anticipated later this year Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab for first-line (1L) treatment of recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC). In the 1L combination arm, treatment with petosemtamab plus pembrolizumab achieved a median overall survival (OS) of 28.2 months, associated with an overall response rate (ORR) of 63% and median progression free survival (mPFS) of 9.0 months in efficacy-evaluable patients (n=43), including a complete response (CR) rate of 19%.

GlobeNewsWire • Oct 26, 2026

Genmab Shares Jump After Positive Cancer Study Results

The Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.

WSJ • Oct 26, 2026

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.

Zacks Investment Research • Oct 26, 2026

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-up of 5.9 months in the first-line (1L) setting and 7.1 months in.

Business Wire • Oct 25, 2026